Uni-Bio Science Group Ltd Receives NMPA Approval for Diquafosol Sodium Eye Drops

21 May 2025 – Uni-Bio Science Group Limited, a company specializing in biopharmaceuticals within the health care sector, has announced a significant milestone in its ophthalmology portfolio. The company’s new product, 金因康® (Diquafosol Sodium Eye Drops), has received marketing approval from the China National Medical Products Administration (NMPA) [Approval Number: 國藥准字H20254149]. This approval marks a crucial step in addressing the growing demand for innovative treatments in China’s dry eye syndrome market, which affects an estimated 360 million individuals.

Diquafosol Sodium Eye Drops are Uni-Bio’s second ophthalmology drug following GeneSoft®, and they target the underlying causes of dry eye syndrome. The product works by activating P2Y2 receptors, which stimulates the secretion of tear fluid and mucin, thereby improving the tear layer and providing relief to patients.

Company Overview

Uni-Bio Science Group Limited is a bio-science related business listed on the Hong Kong Stock Exchange. The company focuses on the research, development, and commercialization of biopharmaceuticals using recombinant DNA and other advanced technologies. As of 19 May 2025, the company’s close price was HKD 0.077, with a market capitalization of 459,780,000 HKD. The company’s 52-week high was HKD 0.084 on 2 October 2024, and its 52-week low was HKD 0.046 on 5 August 2024. The price-to-earnings ratio stands at 5.72.

This approval from the NMPA is expected to bolster Uni-Bio’s position in the ophthalmology market, providing a strategic advantage in one of the largest markets for dry eye treatments globally. The company continues to focus on expanding its portfolio and addressing unmet medical needs through innovative biopharmaceutical solutions.